Nebenwirkungen · Braftovi
Braftovi 50 mg hard capsules Braftovi 75 mg hard capsules · Abschnitt 4.8 · PDF-Seite 19–20
HOS-140107 · Präparat HOS-098444
19 Colorectal cancer Encorafenib and cetuximab combination In the population treated with encorafenib 300 mg in combination with cetuximab, PPES was reported in 5.1% (11/216) of patients. Most of PPES adverse reactions were Grade 1 in 3.7 % (8/216). Grade 2 events were reported in 0.9% (2/216) of patients, and Grade 3 in 0.5% (1/216) of patients. No dose interruption, dose modification or treatment discontinuation was required. Encorafenib with cetuximab and FOLFOX combination In the pooled EC+FOLFOX population, PPES was reported in 15.8% (41/259) of patients. Most of the events were Grade 1 or 2, and 2.7% (7/259) were Grade 3 events. PPES led to treatment discontinuation in 0.4% (1/259) of patients and led to dose interruption or reduction in 3.5% (9/259) of patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T15:53:00Z · SHA-256 47125c84bb304df39202c4dc14aefc287bbf903ef279d3e55fe42dc6648e375c · Passage a70ddb29d13138315a05f3fe020e17629f9b7f05317f034de928e930188fd3cc · Zeichen 25082–25862 im Abschnitt